Previous Close | 1.24 |
Open | 1.23 |
Bid | 1.10 x 3000 |
Ask | 1.28 x 1000 |
Day's Range | 1.19 - 1.23 |
52 Week Range | 1.06 - 2.12 |
Volume | 103,248 |
Avg. Volume | 297,250 |
Market Cap | 133.042M |
Beta | 1.38 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.31 |
Earnings Date | Feb 15, 2018 - Feb 16, 2018 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.83 |
HAIFA, Israel, March 26, 2018-- Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, announced today that Dr. Roger Jeffs has joined Pluristem’ s strategic advisory ...
HAIFA, Israel, Feb. 27, 2018-- Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, announced today that Frontiers in Medicine has published key findings from a study ...
I am going to take a deep dive into Pluristem Therapeutics Inc’s (NASDAQ:PSTI) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has beenRead More...
HAIFA, Israel, Feb. 07, 2018-- Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today reported financial results for the second quarter of fiscal 2018 ended December ...
The escalating threat of a potential nuclear war between North Korea and the United States has led the Department of Defense to join hands with a clutch of companies in developing more effective medical treatments for acute radiation syndrome. The hostility between the two nations reached a new height last November after Pyongyang fired an intercontinental ballistic missile capable of reaching the U.S. mainland. The DoD's budget allocated $3.9 million of its total funding to develop such medical countermeasures in 2018, an increase of $600,000 from a year ago.
Stock Monitor: CEL-SCI Post Earnings Reporting LONDON, UK / ACCESSWIRE / January 17, 2018 / Active-Investors.com has just released a free research report on Pluristem Therapeutics Inc. (NASDAQ: PSTI ). ...
Assessing Pluristem Therapeutics Inc’s (NASDAQ:PSTI) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met orRead More...
Stock Monitor: Pluristem Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 12, 2017 / Active-Investors issued a free report on VistaGen Therapeutics Inc. (NASDAQ: VTGN ) ("VistaGen"), ...
Pluristem Therapeutics Inc (NASDAQ:PSTI), a biotechnology company based in Israel, led the NasdaqCM gainers with a relatively large price hike in the past couple of weeks. As a stock withRead More...
On a per-share basis, the Haifa, Israel-based company said it had a loss of 8 cents. In the final minutes of trading on Tuesday, the company's shares hit $1.47. A year ago, they were trading at $1.51. ...
NEW YORK, NY / ACCESSWIRE / October 12, 2017 / All three major indexes closed at record highs Wednesday after minutes from the most recent Federal Reserve Meeting suggested a December rate hike was not ...
Pluristem Therapeutics Inc. (PSTI) saw its shares rise over 5% on the day.
LONDON, UK / ACCESSWIRE / September 29, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Pluristem Therapeutics Inc. (NASDAQ: PSTI ) ("Pluristem"), which can be viewed ...
Research Desk Line-up: Pluristem Therapeutics Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 20, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines ...
Pluristem Therapeutics' (PSTI) phase III study of PLX-PAD cells in patients with critical limb ischemia granted Fast Track designation by the FDA.